Company: MLTX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001821586-25-000022
Chunk: 2

Company: MoonLake Immunotherapeutics
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' Equity Noncontrolling InterestsTotal Equity (in thousands except share data)SharesAmountSharesAmountBalance at January 1, 202460,466,453 $6 2,505,476 $— $609,969 $(116,657)$2,358 $495,676 $17,815 $513,491 Share-based compensation under the Employee Share Participation Plan and MoonLake Immunotherapeutics 2022 Equity Incentive Plan— — — — 1,693 — — 1,693 (16)1,677 Buyback of unvested MoonLake AG Common Shares by MoonLake AG into treasury following an employee contract termination— — — — 113 — 1 114 (114)— Capital injection from MoonLake to MoonLake AG— — — — (4,667)— — (4,667)3,057 (1,610)Cancellation of MoonLake Class C Ordinary Shares following an employee contract termination in MoonLake AG— — (16,853)— — — — — — — Issuance of Class A Ordinary Shares, net of transaction costs914,828 — — — 52,540 — — 52,540 — 52,540 Net loss for the three months ended March 31, 2024— — — — — (13,673)— (13,673)(302)(13,975)Other comprehensive income— — — — — — 257 257 6 263 Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares1,493,356 — (1,493,356)— 10,537 — 76 10,613 (10,613)— Balance at March 31, 202462,874,637 $6 995,267 $— $670,185 $(130,330)$2,692 $542,553 $9,833 $552,386 Share-based compensation under the Employee Share Participation Plan and MoonLake Immunotherapeutics 2022 Equity Incentive Plan— $— — $— $1,813 $— $— $1,